Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda And Ajinomoto Initiate Phase III Trials For Once-monthly Risedronate

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical and Tokyo-based Ajinomoto and commenced a Phase III trial for once-monthly risedronate for osteoporosis. Marketed under Actonel by Eisai and Benet by Takeda in Japan, risedronate currently has once-daily and once-weekly formulations. The once-monthly is expected to be more convenient for patients. The sales for Benet's once-weekly formulation were ¥16.3 billion in 2008, accounting for 65 percent of Benet sales. Ajinomoto expects the monthly dosage will tap into the market trend for less frequency of administration. The once-monthly risedronate has been approved and marketed in the U.S., Australia and South Korea. Japan's osteoporosis drug market is worth roughly ¥170 billion. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts